GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2009

Nanogen Licenses Technology to Quest for In Vitro Diagnostic Testing

  • Quest Diagnostics obtained rights to use and sell products and services incorporating Nanogen’s MGB (minor groove binder) Probe technology. According to the end-user license agreement, Quest will pay an up-front fee and royalties on tests sold using this technology. Quest will be able to use this platform in human in vitro diagnostic testing.


Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?